Review: Leishmaniasis in the United States: Treatment in 2012 Review uri icon

Overview

MeSH Major

  • Antiprotozoal Agents
  • Leishmaniasis

abstract

  • Although civilian physicians in the United States seldom encounter patients with leishmaniasis, therapeutic advances in endemic regions have opened the door to approaches that can be applied in this country. Advances revolve around the use of oral miltefosine in all forms of leishmaniasis and the use of short-course intravenous liposomal amphotericin B in visceral and possibly cutaneous infection. Lengthy, traditional intravenous treatment with pentavalent antimony (sodium stibogluconate) still has a role in the United States; however, although expensive, miltefosine and liposomal amphotericin B are considerably more appealing selections for initial therapy.

publication date

  • March 2012

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3284358

Digital Object Identifier (DOI)

  • 10.4269/ajtmh.2012.11-0682

PubMed ID

  • 22403313

Additional Document Info

start page

  • 434

end page

  • 40

volume

  • 86

number

  • 3